Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for ...

Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it ...

Cortigent is a precision neurostimulation technology that seeks to provide an artificial vision for blind people. Jonathan Adams has served as Cortigent's CEO since 2023 and will retain that ...

Company plans to spin off Cortigent, Inc., a division that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA ...

Cortigent anticipates extending the EFS by one year to allow further observation of the long-term safety, reliability, and visual function provided by the Orion System. The Orion System is an ...

Vivani Medical reports successful GLP-1 implant insertions, financial updates, and plans to spin off Cortigent as a separate company. Vivani Medical, Inc. announced that all subjects in its NPM ...

A Quick Take On Cortigent, Inc. Cortigent, Inc. (CRGT) has filed to raise $17.25 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing a medical ...

On March 12, 2025, the Company announced that it intends to spin off Cortigent, Inc. (“Cortigent”), a Delaware corporation and its wholly owned subsidiary, that develops brain implant ...

About Cortigent, Inc. Vivani’s wholly owned subsidiary, Cortigent, Inc. (“Cortigent”), is developing precision neurostimulation systems intended to help patients recover critical body functions.